BR112016022333A2 - Sulfamidase modificada e produção da mesma - Google Patents

Sulfamidase modificada e produção da mesma

Info

Publication number
BR112016022333A2
BR112016022333A2 BR112016022333A BR112016022333A BR112016022333A2 BR 112016022333 A2 BR112016022333 A2 BR 112016022333A2 BR 112016022333 A BR112016022333 A BR 112016022333A BR 112016022333 A BR112016022333 A BR 112016022333A BR 112016022333 A2 BR112016022333 A2 BR 112016022333A2
Authority
BR
Brazil
Prior art keywords
sulfamidase
modified
production
modified sulfamidase
sulphamidase
Prior art date
Application number
BR112016022333A
Other languages
English (en)
Inventor
Berghard Charlotta
Nordling Erik
Svensson Gelius Stefan
TJERNBERG Agneta
Original Assignee
Swedish Orphan Biovitrum Ab Publ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Swedish Orphan Biovitrum Ab Publ filed Critical Swedish Orphan Biovitrum Ab Publ
Publication of BR112016022333A2 publication Critical patent/BR112016022333A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y310/00—Hydrolases acting on sulfur-nitrogen bonds (3.10)
    • C12Y310/01—Hydrolases acting on sulfur-nitrogen bonds (3.10) acting on sulfur-nitrogen bonds (3.10.1)
    • C12Y310/01001—N-Sulfoglucosamine sulfohydrolase (3.10.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SULFAMIDASE MODIFICADA E PRODUÇÃO DA MESMA. São aqui revelados uma sulfamidase modificada, uma composição compreendendo uma sulfamidase modificada, assim como métodos para preparar uma sulfamidase modificada e o uso terapêutico de uma tal sulfamidase. Em particular, a presente revelação diz respeito a uma sulfamidase modificada não compreendendo substancialmente quaisquer epítopos para receptores de reconhecimento de glicano, permitindo deste modo o transporte da sulfamidase através da barreira hematoencefálica de um mamífero, em que a sulfamidase tem atividade catalítica no cérebro do mamífero.
BR112016022333A 2014-04-01 2015-04-01 Sulfamidase modificada e produção da mesma BR112016022333A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14162996 2014-04-01
PCT/EP2015/057256 WO2015150490A1 (en) 2014-04-01 2015-04-01 Modified sulfamidase and production thereof

Publications (1)

Publication Number Publication Date
BR112016022333A2 true BR112016022333A2 (pt) 2017-08-15

Family

ID=50389999

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016022333A BR112016022333A2 (pt) 2014-04-01 2015-04-01 Sulfamidase modificada e produção da mesma

Country Status (30)

Country Link
US (2) US9982243B2 (pt)
EP (2) EP3401325A1 (pt)
JP (1) JP6594896B2 (pt)
KR (1) KR20160138282A (pt)
CN (1) CN106414727A (pt)
AU (1) AU2015239126B2 (pt)
BR (1) BR112016022333A2 (pt)
CA (1) CA2943140A1 (pt)
CL (1) CL2016002469A1 (pt)
CY (1) CY1120697T1 (pt)
DK (1) DK2970413T3 (pt)
ES (1) ES2687262T3 (pt)
HK (1) HK1231510A1 (pt)
HR (1) HRP20181507T1 (pt)
HU (1) HUE039691T2 (pt)
IL (1) IL247978A0 (pt)
LT (1) LT2970413T (pt)
MA (1) MA38816B1 (pt)
MX (1) MX368947B (pt)
PH (1) PH12016501812A1 (pt)
PL (1) PL2970413T3 (pt)
PT (1) PT2970413T (pt)
RS (1) RS57842B1 (pt)
RU (1) RU2708026C2 (pt)
SA (1) SA516371859B1 (pt)
SG (1) SG11201608025QA (pt)
SI (1) SI2970413T1 (pt)
UA (1) UA120432C2 (pt)
WO (1) WO2015150490A1 (pt)
ZA (1) ZA201606492B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2970413T (lt) 2014-04-01 2018-10-10 Swedish Orphan Biovitrum Ab (Publ) Modifikuota sulfamidazė ir jos gamyba
CN108291246A (zh) * 2015-10-01 2018-07-17 瑞典孤儿比奥维特鲁姆有限公司 修饰的溶酶体蛋白及其产生
CA3076369A1 (en) 2017-10-02 2019-04-11 Denali Therapeutics Inc. Fusion proteins comprising enzyme replacement therapy enzymes
WO2019145500A1 (en) 2018-01-26 2019-08-01 Swedish Orphan Biovitrum Ab (Publ) Method of treatment
WO2020047282A1 (en) 2018-08-29 2020-03-05 University Of Copenhagen Lysosomal enzymes modified by cell based glycoengineering
EP3741867A1 (en) 2019-05-24 2020-11-25 Swedish Orphan Biovitrum AB (Publ) Sulfatase activity assay
MX2023004335A (es) 2020-10-14 2023-05-04 Denali Therapeutics Inc Proteinas de fusion que comprenden enzimas sulfoglucosamina sulfohidrolasa y metodos de estas.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5863782A (en) 1995-04-19 1999-01-26 Women's And Children's Hospital Synthetic mammalian sulphamidase and genetic sequences encoding same
JP4503706B2 (ja) 1996-06-07 2010-07-14 ポニアード ファーマシューティカルズ，インコーポレイティド グリコシル化が改質されたヒト化抗体
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
WO2003032913A2 (en) 2001-10-16 2003-04-24 Symbiontics Inc. Methods and compositions for targeting proteins across the blood brain barrier
WO2004003176A2 (en) 2002-07-01 2004-01-08 The Kenneth S. Warren Institute, Inc. Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs
US20090041741A1 (en) * 2007-03-06 2009-02-12 Saint Louis University Modified enzyme and treatment method
KR101744142B1 (ko) * 2008-01-18 2017-06-07 바이오마린 파머수티컬 인크. 활성이고 높은 정도로 인산화된 인간 리소좀 술파타아제 효소의 제조 및 그 용도
EP2394667A1 (en) * 2010-06-10 2011-12-14 Laboratorios Del Dr. Esteve, S.A. Vectors and sequences for the treatment of diseases
JP6023073B2 (ja) * 2010-12-22 2016-11-09 フォンダッツィオーネ・テレソン ムコ多糖症におけるｃｎｓ病変を処置するための治療戦略
EP2721151B1 (en) * 2011-06-20 2017-12-06 Mount Sinai School Of Medicine Anti-tnf-therapy for the mucopolysaccharidoses and other lysosomal disorders
WO2014194427A1 (en) 2013-06-06 2014-12-11 Angiochem Inc. Targeted iduronate-2-sulfatase fusion proteins
US20140377246A1 (en) 2013-06-19 2014-12-25 Carol Ann Foundation and International Morquio Organization Enzyme replacement therapy for treating mps vii related bone lesions using a chemically modified enzyme
LT2970413T (lt) 2014-04-01 2018-10-10 Swedish Orphan Biovitrum Ab (Publ) Modifikuota sulfamidazė ir jos gamyba

Also Published As

Publication number Publication date
EP2970413A1 (en) 2016-01-20
JP6594896B2 (ja) 2019-10-23
MA38816B1 (fr) 2018-10-31
RU2016140844A3 (pt) 2018-10-11
RU2708026C2 (ru) 2019-12-03
CL2016002469A1 (es) 2017-12-15
ES2687262T3 (es) 2018-10-24
PL2970413T3 (pl) 2018-12-31
AU2015239126B2 (en) 2019-05-02
US9982243B2 (en) 2018-05-29
CY1120697T1 (el) 2019-12-11
KR20160138282A (ko) 2016-12-02
RU2016140844A (ru) 2018-05-10
MA38816A (fr) 2016-01-20
SA516371859B1 (ar) 2019-01-17
DK2970413T3 (en) 2018-10-15
IL247978A0 (en) 2016-11-30
JP2017514462A (ja) 2017-06-08
RS57842B1 (sr) 2018-12-31
HUE039691T2 (hu) 2019-01-28
MX368947B (es) 2019-10-22
US20160230155A1 (en) 2016-08-11
MX2016012910A (es) 2017-07-14
ZA201606492B (en) 2019-02-27
LT2970413T (lt) 2018-10-10
EP2970413B1 (en) 2018-07-04
SG11201608025QA (en) 2016-10-28
HRP20181507T1 (hr) 2018-11-16
US20180320152A1 (en) 2018-11-08
SI2970413T1 (sl) 2018-10-30
HK1231510A1 (zh) 2017-12-22
CA2943140A1 (en) 2015-10-08
AU2015239126A1 (en) 2016-10-27
CN106414727A (zh) 2017-02-15
PT2970413T (pt) 2018-10-23
WO2015150490A1 (en) 2015-10-08
PH12016501812A1 (en) 2017-07-24
UA120432C2 (uk) 2019-12-10
EP3401325A1 (en) 2018-11-14

Similar Documents

Publication Publication Date Title
BR112016022333A2 (pt) Sulfamidase modificada e produção da mesma
HK1245010A1 (zh) 用於治療疾病的遺傳修飾的細胞、組織和器官
CO2018006714A2 (es) 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa
MY179194A (en) Process for preparing therapeutic nanoparticles
MX365939B (es) Moduladores del transporte nuclear y usos de los mismos.
MX2021014128A (es) Polimorfos de selinexor.
NI201500036A (es) Nanopartículas terapéuticas que comprenden un agente terapéutico y métodos para realizarlas y usarlas.
ES2765949T8 (es) Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer
MX2021008755A (es) Un anticuerpo anti-tau para usarse al tratar una tauopatia.
MX2016008448A (es) Conjugados de var2csa-farmaco.
NZ702663A (en) Nuclear transport modulators and uses thereof
BR112015022041A2 (pt) derivados substituídos de 3-fenilpropilamina para o tratamento de doenças e distúrbios oftálmicas
CU20160020A7 (es) Derivados de imidazoquinolinas sustituidas inhibidores de mek para el tratamiento del cáncer
MX2020011415A (es) Metodos de usar zscan4 para rejuvenecer celulas humanas.
BR112012032008A2 (pt) anticorpos s100a4 e usos terapêuticos do mesmo
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
NI201500050A (es) Benzamidas
BR112015007843A2 (pt) método para a preparação de um polímero, polímero, artigo e método de preparação de um artigo
BR112015024860A2 (pt) vacinas que compreendem polipeptídeos de leishmania para o tratamento e diagnóstico de leishmaniose
UY35438A (es) Procedimiento para preparar inhibidores de la glucosilceramida sintasa.
BR112016006532A2 (pt) processo para preparação de benzisotiazolinonas
BR112016009962A2 (pt) superagonistas de ação prolongada de hormônio glicoproteico
MX2016002502A (es) Composiciones farmaceuticas de bendamustina.
MX2016002186A (es) Proceso para preparar dronedarona y sales de la misma.
BR112016013419A2 (pt) composições de liberação retardada de linaclotida

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]